
TELA Bio, Inc.: updates and filings
Price
$0.69
November 20, 2026Market cap $40M
What Ploutos Investor adds for TELA Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 10, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
- 31MonPeopleRestructuring costs, officer or director change, Regulation FD disclosureDocument
- 13ThuPeopleOfficer or director change (amendment)Document
- 11TueReportQuarterly report · for the period to Jun 30, 2026Document
- 10MonResultsResults of operationsDocument
- 4TuePeopleOfficer or director changeDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026FilingFormEFFECT
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Shelf registration for future offeringsFormS-3
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Oct 8, 2026Shareholder voteForm8-K
- Oct 6, 2026Other material eventsForm8-K
- Oct 5, 2026Other material eventsForm8-K
- Sep 29, 2026Material agreement enteredForm8-K
- Sep 18, 2026Delisting noticeForm8-K
- Sep 14, 2026Annual meeting proxy statementFormDEF 14A
- Sep 4, 2026Preliminary proxy statementFormPRE 14A
- Aug 31, 2026Restructuring costs, officer or director change, Regulation FD disclosureForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Officer or director change (amendment)Form8-K/A
- Aug 11, 2026Shares registered for employeesFormS-8
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 11, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 10, 2026Results of operationsForm8-K
- Aug 4, 2026Shares registered for employeesFormS-8
- Aug 4, 2026Officer or director changeForm8-K
- Jun 11, 2026Officer or director change, shareholder voteForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | EFFECT | Filing | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Oct 8, 2026 | 8-K | Shareholder vote | Document |
| Oct 6, 2026 | 8-K | Other material events | Document |
| Oct 5, 2026 | 8-K | Other material events | Document |
| Sep 29, 2026 | 8-K | Material agreement entered | Document |
| Sep 18, 2026 | 8-K | Delisting notice | Document |
| Sep 14, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Sep 4, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Aug 31, 2026 | 8-K | Restructuring costs, officer or director change, Regulation FD disclosure | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | 8-K/A | Officer or director change (amendment) | Document |
| Aug 11, 2026 | S-8 | Shares registered for employees | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 11, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 10, 2026 | 8-K | Results of operations | Document |
| Aug 4, 2026 | S-8 | Shares registered for employees | Document |
| Aug 4, 2026 | 8-K | Officer or director change | Document |
| Jun 11, 2026 | 8-K | Officer or director change, shareholder vote | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 6, 2012.
The full analysis
What do TELA Bio's filings show?
The filings are where every one of TELA Bio's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.